Print this page    •   Back to Web version of article

Comparing Protease Combinations

May 1996

Reported maximum average reductions in plasma
RNA with selected protease inhibitor combinations
(in treament naive/experienced* individuals)
SQV.6 logS. Vella
SQV(new formulation)1.5 logRoche
RTV1.2-1.9 logAbbott
IDV1.2-2.0 logMerck
NFV1.5 logMarkowitz
SQV+AZT1.0 logS. Vella
SQV+ddC.6 logRoche NV*
SQV+AZT+ddC.8 logACTG 229*
RTV+AZT1.2 logAbbott
RTV+AZT+ddC2.0-2.5 logLeibowich
IDV+AZT1.4-1.5 logMerck
IDV+AZT+ddl2.9 logMerck
IDV+AZT3TC>2.0 logMerck 035*
NFV+d4T2.4-2.6 logChapman




This article was provided by Treatment Action Group. It is a part of the publication TAGline. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art1465.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.